Allergic rhinitis is a widespread condition, affecting 20 to 40 million persons in the United States each year, including up to 40% of children.1 The direct costs of treatment and indirect costs related to worker absences and loss of productivity are significant. In 1995, the total economic impact of allergic rhinitis was estimated at $2.7 billion, not including the costs of associated problems, such as rhinosinusitis and asthma.1 Among children, rhinitis is a significant cause of lost school days.1
In part 1 of this article, I will discuss the use of antihistamines, decongestants, anticholinergics, and cromolyn in the management of allergic rhinitis. In part 2, to be published in a coming issue of The Journal of Respiratory Diseases, I will review the use of intranasal corticosteroids, leukotriene modifiers, and combination therapy; I also will discuss the role of allergen immunotherapy.
Allergic rhinitis is an inflammatory disease of the nasal mucosa; symptoms include sneezing, itching, rhinorrhea, and nasal congestion. Active symptoms and the underlying inflammation are the result of a process that begins when mast cells in the nasal mucosa of sensitized persons bind allergens through IgE expressed on the cell surface. Binding causes mast cell degranulation and the release of a host of preformed and newly formed mediators, including histamine and cysteinyl leukotrienes, which are important targets for drug intervention (Figure).
The events immediately following allergen binding to IgE cause the early-phase allergic response and provoke symptoms within minutes of allergen exposure. Increased vascular permeability of nasal vessels, along with glandular stimulation and vessel dilation, results in watery rhinorrhea, mucinous secretion, and nasal airways occlusion; nerve stimulation leads to nasal itching and sneezing.
A late-phase response develops hours later. In this phase, the mediators that were generated dur- ing the early response induce a variety of migratory cells--including eosinophils, basophils, and neutrophils--to infiltrate the nasal mucosa.2 Activation of these cells elicits and sustains an inflammatory response that causes the tissue damage and persistent nasal blockage characteristic of chronic allergic reaction.
Allergic rhinitis is characterized as seasonal or perennial according to whether symptoms appear in a predictable cyclic pattern or throughout the year. Seasonal allergic rhinitis is the result of IgE-mediated responses to seasonal aeroallergens, typically pollens and molds. In perennial allergic rhinitis, the response is to aeroallergens that persist in the environment year-round, such as house dust mites, molds, and animal dander. Nasal obstruction may be the dominant symptom of chronic rhinitis, which is attributable to the ongoing inflammatory response associated with perennial allergy.1
Allergic rhinitis can sometimes be confused with nonallergic, non-IgE-mediated forms of rhinitis, which include infectious rhinitis, vasomotor rhinitis, occupational rhinitis, and nonallergic rhinitis with eosinophilia syndrome.1 The evaluation of rhinitis begins with a careful history, followed by a physical examination that includes examination of the nasal passageways and secretions and determination of whether nasal polyps are present.
An important step in making an unequivocal diagnosis of allergic rhinitis is testing for specific IgE. This is usually accomplished by skin testing to allergens, although in vitro tests for specific subclasses of IgE can also be performed. Identification of a specific allergen(s) is an invaluable guide to appro- priate avoidance measures and to immunotherapy.1
1. Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol. 1998;81(5 pt 2):478-518.
2. Togias A, Naclerio RM, Proud D, et al. Studies on the allergic and nonallergic nasal inflammation. J Allergy Clin Immunol. 1988;81(5 pt 1):782-790.
3. International Consensus Report on the diagnosis and management of rhinitis. International Rhinitis Management Working Group. Allergy. 1994;49(19 suppl):1-34.
4. Sheikh A, Hurwitz B. House-dust mite avoidance measures for perennial allergic rhinitis. Cochrane Database Syst Rev. 2001;4:CD001563.
5. Malmberg H, Binder E, Fraki J, et al. Nasal reactions elicited by unilateral allergen challenge. Acta Otolaryngol. 1989;107:446-449.
6. Chung JH, deTineo ML, Naclerio RM, et al. Low dose clemastine inhibits sneezing and rhinorrhea during the early nasal allergic reaction. Ann Allergy Asthma Immunol. 1997;78:307-312.
7. Greiff L, Persson CG, Andersson M. Desloratadine reduces allergen challenge-induced mucinous secretion and plasma exudation in allergic rhinitis. Ann Allergy Asthma Immunol. 2002;89:413-418.
8. Frossard N, Lacronique J, Melac M, et al. Onset of action in the nasal antihistaminic effect of cetirizine and loratadine in patients with allergic rhinitis. Allergy. 1997;52:205-209.
9. Howarth PH, Stern MA, Roi L, et al. Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol. 1999;104:927-933.
10. Day JH, Briscoe MP, Rafeiro E, et al. Randomized double-blind comparison of cetirizine and fexofenadine after pollen challenge in the Environmental Exposure Unit: duration of effect in subjects with seasonal allergic rhinitis. Allergy Asthma Proc. 2004;25:59-68.
11. Connell JT. A novel method to assess antihistamine and decongestant efficacy. Ann Allergy. 1979;42:278-285.
12. Weiler JM, Meltzer EO, Benson PM, et al. A dose-ranging study of the efficacy and safety of azelastine nasal spray in the treatment of seasonal allergic rhinitis with an acute model. J Allergy Clin Immunol. 1994;94(6 pt 1):972-980.
13. Ratner PH, Findlay SR, Hampel F Jr, et al. A double-blind, controlled trial to assess the safety and efficacy of azelastine nasal spray in seasonal allergic rhinitis. J Allergy Clin Immunol. 1994; 94:818-825.
14. Storms WW, Pearlman DS, Chervinsky P, et al. Effectiveness of azelastine nasal solution in seasonal allergic rhinitis. Ear Nose Throat J. 1994;73:382-386, 390-394.
15. LaForce C, Dockhorn RJ, Prenner BM, et al. Safety and efficacy of azelastine nasal spray (Astelin NS) for seasonal allergic rhinitis: a 4-week comparative multicenter trial. Ann Allergy Asthma Immunol. 1996;76:181-188.
16. Banov CH, Lieberman P; Vasomotor Rhinitis Study Groups. Efficacy of azelastine nasal spray in the treatment of vasomotor (perennial nonallergic) rhinitis. Ann Allergy Asthma Immunol. 2001;86:28-35.
17. Berger WE, White MV; Rhinitis Study Group. Efficacy of azelastine nasal spray in patients with an unsatisfactory response to loratadine. Ann Allergy Asthma Immunol. 2003; 91:205-211.
18. LaForce CF, Corren J, Wheeler WJ, Berger WE; Rhinitis Study Group. Efficacy of azelastine nasal spray in seasonal allergic rhinitis patients who remain symptomatic after treatment with fexofenadine. Ann Allergy Asthma Immunol. 2004;93:154-159.
19. Empey DW, Young GA, Letley E, et al. Dose-response study of the nasal decongestant and cardiovascular effects of pseudoephedrine. Br J Clin Pharmacol. 1980;9: 351-358.
20. Witek TJ Jr, Canestrari DA, Hernandez JR, et al. Superficial nasal mucosal blood flow and nasal patency following topical oxymetazoline hydrochloride. Ann Allergy. 1992;68: 165-168.
21. Graf P, Hallen H, Juto JE. Four-week use of oxymetazoline nasal spray (Nezeril) once daily at night induces rebound swelling and nasal hyperreactivity. Acta Otolaryngol. 1995; 115:71-75.
22. Mullol J, Raphael GD, Lundgren JD, et al. Comparison of human nasal mucosal secretion in vivo and in vitro. J Allergy Clin Immunol. 1992;89:584-592.
23. Borum S, Becker B, Mygind N, Borum P. Comparison between the effect of ipratropium bromide as a pressurized aerosol and as an aqueous pump spray on methacholine-induced rhinorrhoea. Rhinology. 1996;34: 198-200.
24. Meltzer EO, Orgel HA, Bronsky EA, et al. Ipratropium bromide aqueous nasal spray for patients with perennial allergic rhinitis: a study of its effect on their symptoms, quality of life, and nasal cytology. J Allergy Clin Immunol. 1992;90:242-249.
25. Kaiser HB, Findlay SR, Georgitis JW, et al. Long-term treatment of perennial allergic rhinitis with ipratropium bromide nasal spray 0.06%. J Allergy Clin Immunol. 1995;95(5 pt 2):1128-1132.
26. Jokinen K, Sipila P. Intranasal ipratropium in the treatment of vasomotor rhinitis. Rhinology. 1983;21:341-345.
27. Ratner PH, Ehrlich PM, Fineman SM, et al. Use of intranasal cromolyn sodium for allergic rhinitis. Mayo Clin Proc. 2002;77:350-354.
28. Meltzer EO; NasalCrom Study Group. Efficacy and patient satisfaction with cromolyn sodium nasal solution in the treatment of seasonal allergic rhinitis: a placebo-controlled study. Clin Ther. 2002;24:942-952.
29. Schuller DE, Selcow JE, Joos TH, et al. A multicenter trial of nedocromil sodium, 1% nasal solution, compared with cromolyn sodium and placebo in ragweed seasonal allergic rhinitis. J Allergy Clin Immunol. 1990; 86(4 pt 1):554-561.